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Introduction: Lung cancer remains the leading cause of cancer-
related death with poor survival due to the late stage at which lung
cancer is typically diagnosed. Given the clinical burden from lung
cancer and the relatively favorable survival associated with early-
stage lung cancer, biomarkers for early detection of lung cancer are
of important potential clinical benefit.
Methods: We performed a global lung cancer serum biomarker
discovery study using liquid chromatography-tandem mass spec-
trometry in a set of pooled non-small cell lung cancer case sera and
matched controls. Immunoaffinity subtraction was used to deplete
the top most abundant serum proteins; the remaining serum proteins
were subjected to trypsin digestion and analyzed in triplicate by
liquid chromatography-tandem mass spectrometry. The tandem
mass spectrum data were searched against the human proteome
database, and the resultant spectral counting data were used to
estimate the relative abundance of proteins across the case/control
serum pools. The spectral counting-derived abundances of some
candidate biomarker proteins were confirmed with multiple reaction
monitoring mass spectrometry assays.
Results: A list of 49 differentially abundant candidate proteins was
compiled by applying a negative binomial regression model to the
spectral counting data (p  0.01). Functional analysis with Ingenu-
ity Pathway Analysis tools showed significant enrichment of inflam-
matory response proteins, key molecules in cell-cell signaling and
interaction network, and differential physiological responses for the
two common non-small cell lung cancer subtypes.
Conclusions: We identified a set of candidate serum biomarkers
with statistically significant differential abundance across the lung
cancer case/control pools, which, when validated, could improve
lung cancer early detection.
Key Words: Lung cancer, Serum biomarkers, liquid chromatography-
mass spectrometry/mass spectrometry.
(J Thorac Oncol. 2011;6: 725–734)
Lung cancer is the leading cause of cancer death in theUnited States. The majority of patients with lung cancer
are diagnosed at advanced stage and have less than 15%
5-year survival rate. In contrast, early-stage lung cancer has
relatively favorable survival. A recent review reported that
stage IA patients, with tumor size less than 10 mm, experi-
enced an 86% overall and 100% cancer-specific 5-year sur-
vival with complete resection.1 Despite these statistics, lung
cancer screening is currently not recommended due to lack of
good screening modalities.2 Both chest radiographs and spu-
tum cytology have low sensitivity, and clinical trials failed to
show a benefit for overall survival in the screened population.
New computed tomography (CT) imaging technology is
much more sensitive.3 Nevertheless, CT scans suffer from
low specificity due to frequent detection of benign pulmonary
nodules.4,5 Although published studies have demonstrated
elevated serum levels of some proteins, such as CYFRA 21-1,
CEA, and TPA,6–8 none of them are sensitive and specific
enough for clinical use.
Proteomics has advanced rapidly, fueled by increas-
ingly robust technologies, along with revolutions in bioinfor-
matics methods for analyzing the high-dimensionality data.
With the coupling of advanced capillary-based liquid chro-
matography (LC)-separation online with tandem mass spec-
trometry (MS/MS) analyses, proteomics biomarker discovery
workflows now permit the identification and relative quanti-
tation of thousands of proteins in complex biofluids such as
serum. This enabling technology has been recently applied
to the search for lung cancer serum biomarkers.9,10 A
number of lung cancer-altered serum proteins were re-
ported from these studies. Nevertheless, both studies had
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relatively small sample size, ranging from three to five
individual case or control subjects. In addition, both stud-
ies limited the comparison to patients with lung cancer and
healthy controls only, without inclusion of high-risk sub-
jects such as those with indeterminate CT-detected nodules
and/or compromised pulmonary function.
Aiming to identify serum-based biomarkers that could
predict lung cancer risk in high-risk subjects and particularly
in patients with pulmonary nodules, we applied a label-free
LC-MS/MS workflow to a large set of serum pools obtained
from patients with non-small cell lung cancer (NSCLC),
clinical controls with CT-detected benign pulmonary nod-
ules, and healthy controls. Relative quantitation of protein
abundance was carried out using spectral counting, i.e., the
number of MS/MS spectra resulting in the identification of
each protein’s corresponding peptides. The rationale for spec-
tral counting-derived protein abundance is that proteins in
higher abundance will result in more proteolytic peptides
detected by tandem MS and subsequently identified by data-
base searching.11,12 Although intuitively attractive, spectral
counting may be influenced by differential ionization and/or
fragmentation efficiency of different peptides, underrepresen-
tation of lower intensity peptides, and dynamic exclusion of
high-intensity peptides. Nevertheless, it has been demon-
strated that spectral counting linearly correlates with protein
abundance over a dynamic range of two orders of magni-
tude11 and is capable of detecting relative changes in protein
abundances, especially for proteins with higher spectral
counts.12 Lung cancer-selective proteins were identified using
a negative binomial regression model,13 a relaxed Poisson
regression model for count data overdispersed in regard to the
Poisson distribution. The spectral counting-derived abun-
dances of some candidate proteins were confirmed using
quantitative mass spectrometry by multiple reaction monitor-
ing (MRM).14,15
MATERIALS AND METHODS
Blood Sample Collection, Processing, and
Storage
Peripheral blood samples were obtained from patients
with NSCLC and control subjects recruited as part of Uni-
versity of Pittsburgh Cancer Institute Lung Nodule/Lung
Cancer Proteomics/Genomics Research Registry, together
with the Pittsburgh Lung Screening Study (PLuSS), sup-
ported by the University of Pittsburgh Cancer Institute Lung
Cancer SPORE. The University of Pittsburgh Institutional
Review Board approved all aspects of the study. A total of 54
newly diagnosed patients with NSCLC (31 adenocarcinoma
and 23 squamous cell carcinoma), 54 clinical controls with a
CT-detected nodule but only with nonmalignant lung disease
as confirmed by biopsy, and 106 healthy PLuSS controls
were selected for the current study. The clinical and demo-
graphic characteristics of the participants are summarized in
Table 1. The significances for the demographic differences
between cases and controls were determined using Fisher’s
exact test (age) or the 2 test (gender and smoking history).
None of these demographic characteristics were significantly
different between cases and controls, with p values of 0.058,
0.208, and 0.782 for age, gender, and smoking history,
respectively. Blood samples were collected, processed, ali-
quoted, and stored using the same rigorously validated Lung
Cancer SPORE protocol. Aliquoted serum samples were
frozen at 80°C and were not thawed before the sample
pooling procedures; the pooled samples were then refrozen at
80°C until use.
Lung Cancer Case/Control Discovery Serum
Sample Pooling Design
Given the intensive preparative and analytical work-
flow of LC-MS/MS analysis, the individual serum samples
were pooled into nine adenocarcinoma pools (P01–P09), six
squamous cell carcinoma pools (P11–P16), eight clinical
control pools (P17–P24), and eight healthy control pools
(P25–P32), according to histological subtypes, cancer stage,
gender, and smoking status (active versus exsmoker, with
never smoker cases excluded). The overall goal of the pool-
ing strategy was to construct case and matched control pools
as homogenous as possible with respect to the most important
clinical and demographic variables describing these samples
(see Supplementary Table S1).
Immunoaffinity Removal of High-Abundant
Proteins
Agilent Human 14 Multiple Affinity Removal spin
cartridges (MARS14, Agilent Technologies, Palo Alto, CA)
were used to deplete the top 14 most abundant serum proteins
TABLE 1. Demographic and Clinical Characteristics of the
Subjects Contributing to the Pooled NSCLC Case (N  54)
and Control (N  160) Samples
Variables No. of Cases (%) No. of Controls (%)
Age (yr)
50 0 (0) 2 (1)
50–54 3 (6) 22 (14)
55–59 5 (9) 36 (23)
60–64 10 (19) 25 (16)
65–69 12 (22) 31 (19)
70–74 13 (24) 18 (11)
75 11 (20) 26 (16)
Gender
Male 23 (43) 84 (52)
Female 31 (57) 76 (48)
Smoking history
Previous 35 (65) 107 (67)
Current 19 (35) 53 (33)
Histology of lung cancers
Adenocarcinoma 31 (57)
Squamous cell carcinoma 23 (43)
Stage of lung cancers
IA/IB 27 (50)
IIA/IIB 8 (15)
IIIA/IIIB 14 (26)
IV 1 (2)
Unknown 4 (7)
NSCLC, non-small cell lung cancer.
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(albumin, immunoglobulin [Ig]G, antitrypsin, IgA, transfer-
rin, haptoglobin, fibrinogen, alpha2-macroglobulin, alpha1-
acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein
AII, complement C3, and transthyretin). For each pool, 16 l
of serum was subjected to MARS14 depletion. The flow-
through fractions were combined and desalted through buffer
exchange with 50 mM NH4HCO3 using ultrafiltration with a
5 kDa molecular weight cutoff (Millipore, Bedford, MA).
The Micro BCA protein assay kit (Thermo Scientific, IL) was
used to determine the protein amount.
In Solution Trypsin Digestion
For each pool, 10 g of desalted serum protein after
MARS14 depletion was resuspended in 50 l 100 mM
NH4HCO3. After reduction with 10-minute boiling in the
presence of 10 mM dithiothreitol and alkylation with 45 mM
iodoacetamide (1-hour incubation in the dark at room tem-
perature), 0.2 g trypsin gold (Promega, Madison, WI)
was added for overnight digestion at 37°C. The resulting
tryptic peptides were desalted with PepClean C-18 Spin
Columns (PIERCE, Rockford, IL), vacuum-dried, and re-
suspended in 20 l 0.1% trifluoroacetic acid (TFA).
LC-MS/MS Analysis of Tryptic Peptides
Tryptic digests were analyzed in triplicate by reverse-
phase LC-MS/MS using a nanoflow LC (Dionex Ultimate
3000, Dionex Corporation, Sunnyvale, CA) coupled online to
a linear ion trap MS (LTQ-XL, ThermoFisher Scientific, San
Jose, CA). Separations were performed using 75 m inner
diameter 360 m outer diameter 15 cm long fused silica
capillary columns (Polymicro Technologies, Phoenix, AZ)
slurry packed in house with 5 m, 300 Å pore size C-18
silica-bonded stationary phase (Jupiter, Phenomenex, Tor-
rance, CA). After injection of 2 g of peptides onto a C-18
trap column (Dionex), the LC column was washed for 3
minutes with mobile phase A (2% acetonitrile and 0.1%
formic acid) at a flow rate of 30 l/min. Peptides were eluted
using a linear gradient of 0.30% mobile phase B (0.1% formic
acid in acetonitrile)/min for 130 minutes, then to 95% B in an
additional 10 minutes, all at a constant flow rate of 250
nl/min. Each full MS scan (m/z, 375–1800) was followed by
seven MS/MS scans (normalized collision energy of 35%) for
the seven most abundant ions. Dynamic exclusion was en-
abled to minimize redundant selection of peptides previously
selected for MS/MS analysis.
Peptide Identification by Database Search for
MS/MS
MS/MS spectra were searched against the UniProt
human proteome database (October 2008 release) from the
European Bioinformatics Institute (http://www.ebi.ac.uk/
integr8) using SEQUEST (ThermoFisher Scientific) with two
variable modifications, 16 Da for methionine oxidation and
57 for carboxyamidomethylation of cysteine. Peptides were
considered legitimately identified if they achieved specific
charge state and proteolytic cleavage-dependent cross-corre-
lation (Xcorr) scores of 1.9 for [MH]
1, 2.2 for [M2H]2,
and 3.5 for [M3H]3 and a minimum delta correlation
score (deltaCn) of 0.08. A false peptide discovery rate of
approximately 4% was determined by searching the primary
tandem MS data using the same criteria against a decoy
database wherein the protein sequences are reversed.
LC-MRM/MS/MS Assays for Selected Peptides
Nano-LC-MRM/MS/MS experiments were performed
on a TSQ Quantum Ultra (ThermoFisher Scientific) coupled
with a nanoflow Dionex Ultimate 3000 liquid chromatogra-
phy system. Solvent A (2% acetonitrile in 0.1% formic acid)
and solvent B (100% acetonitrile in 0.1% formic acid) were
used as the mobile phase. Tryptic digests from 10 g post-
MARS14 depletion serum proteins were resuspended in 20 l
0.1%TFA and analyzed in triplicate (6 l for each injection).
Nano-LC separation was performed using a homemade Jupi-
ter C18 fused silica capillary column (75 m inner diame-
ter  360 m outer diameter  20 cm long) (Polymicro
Technologies, Phoenix, AZ). The peptides were eluted at
350 nl/min with a gradient of 0 to 35% solvent B for 35
minutes, 35 to 95% solvent B for 3 minutes, and 95%
solvent B for 10 minutes. The collision energies were
calculated using the standard equation CE  0.034 
m/z  3.314. The full width at half maximum was set to be
0.7 Da for Q1 and Q3. The dwell time at each transition
was 10 milliseconds, and the width of detection window
for each transition was 1 m/z.
Data Analysis
The spectral counting data were analyzed using a neg-
ative binomial regression model to identify proteins with
differential abundance. To account for the variation in total
spectral counting among different samples, the logarithm of
total spectral count was included as the offset in the model as
shown in Equation 1:
Log (protein spectral count) intercept
 log (total spectral count) *X (1)
where X is a dummy variable for the case/control status. The
significance of features was based on the p value for coeffi-
cient . To increase the confidence for the legitimacy of
spectral counting-based relative quantitation, only proteins
with a minimum of two identified peptides and more than 15
total spectral counts were included for statistical analysis. A
SAS (version 9.2; SAS Institute Inc., Cary, NC) macro using
the GENMOD procedure was written to facilitate batch
processing of the described negative binomial regression. The
false discovery rate was estimated based on the sequential p
value method proposed by Benjamini and Hochberg16 using a
MATLAB (MathWorks Inc., Natick, MA) script. In brief, the
observed p values were ordered from minimum (p1) to
maximum (pm), and the false discovery rate was estimated to
be  associated with pk closest to the p value cutoff used for
feature selection, where k  max {k: pk  *k/m}, and m is
the total number of proteins.
Hierarchical clustering was carried out using MAT-
LAB. The values for spectral counts were standardized for
each protein, so that each had a mean of 0 and a standard
deviation of 1. Both sample distance and protein feature
distance were calculated using Pearson’s correlation, and
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average linkage was used for the clustering of both samples
and protein features. Bioinformatics analysis was carried out
using Ingenuity Pathways Analysis (IPA; Ingenuity Systems
Inc., Redwood City, CA) tools.17
RESULTS
LC-MS/MS Analysis of MARS14-Depleted
Serum Proteins
A total of 31 different serum pools (nine from adeno-
carcinoma cases, six from squamous cell carcinoma cases,
eight from clinical controls, and eight from healthy controls)
were subjected to MARS14 depletion of highly abundant
serum proteins, and tryptic peptides of the postdepleted
serum proteins were analyzed with LC-MS/MS. A total of
56,314 peptides belonging to 20,916 proteins were identified
from the combined 93 LC-MS/MS runs (triplicate runs for
each of the 31 pooled samples) after filtering with our criteria
specified in the “Materials and Methods” section. Identifica-
tion of 11,549 proteins (55%) was based on more than one
peptide. The total number of spectral counts for each sample
after combining triplicate runs varied from 6455 to 9238.
There was no significant difference for the total number of
spectral counts among the four different pooled sample
groups (Kruskal-Wallis test p value of 0.88).
To evaluate the performance of the MARS14 spin
cartridge in the removal of the top 14 proteins, we calculated
the proportions of the spectral counts for these proteins over
the total spectral counts of all identified proteins combining
all 93 LC-MS/MS runs. These proportions were compared
with the proportion of serum protein mass contributed by
these proteins. The contributions to the total spectral counts
(Figure 1B) by the majority of these proteins were much
lower than their contributions for the total serum protein mass
(Figure 1A). The most dramatic performance is for the de-
pletion of serum albumin, which constitutes more than half of
the total serum mass but only contributed to 0.3% of the total
spectral counts in the depleted samples. Nevertheless, the
performance of the MARS14 spin cartridge in the depletion
of apolipoprotein A-I and apolipoprotein A-II was very poor;
their contributions to the total spectral counts were essentially
the same (apolipoprotein A-I) or higher (apolipoprotein A-II)
in the depleted samples compared with their contributions to
the total serum mass. Overall, we observed that the total
proportion of spectral counts for all these 14 proteins was
approximately 7% in the depleted samples, much lower than
the proportion of these proteins in the total serum mass
(95%). These results indicated that, although improvement
is needed for some proteins, overall, the MARS14 spin
cartridge is efficient in the removal of high-abundance serum
proteins. A number of very low-abundant proteins, including
several interleukins, tumor necrosis factor, and troponin T
were detected during our analyses, probably as a result of the
removal of high-abundance proteins by the MARS14 spin
cartridges.
Comparative Data Analysis for Identification of
Lung Cancer-Selective Serum Proteins
To identify serum proteins with differential abundance
in NSCLC case sera versus controls, we combined the total
MS/MS spectra that resulted in legitimate identification of
peptides for a given protein accession across all the pooled
samples (spectral counting) and used the resultant spectral
counting for the relative quantitation of protein abundance.
To increase the confidence of using spectral counting data for
relative quantitation, we only included proteins identified
based on a minimum of two different peptides and with more
than 15 total spectral counts for the combined 93 LC-MS/MS
analysis. A total of 1127 proteins remained after this selec-
tion. A negative binomial model was used to evaluate
whether case/control status (as the independent variable) was
a significant predictor for differential protein spectral counts
(as the dependent variable). For each protein, three negative
binomial model-based comparisons were made between (1)
all case pools versus all control pools; (2) all adenocarcinoma
pools versus all control pools; and (3) all squamous cell
carcinoma pools versus all control pools. The rationale for
making these three comparisons is to identify not only fea-
tures that show differential abundance in both subtypes of
case pools but also to include features that show differential
FIGURE 1. Effectiveness of MARS14 depletion of high-abundance serum proteins. Pie charts show the proportions of serum
protein mass (A) or spectral counts (B) contributed by high-abundance proteins subjected to MARS14 depletion. The observed
spectral counts of lower abundance proteins, which constitute less than 7% of the total serum protein mass, accounted
for 93% of the total spectral counts observed in the immunodepleted samples, demonstrating the overall effectiveness of
MARS14 depletion.
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TABLE 2. List of Differentially Expressed Protein Features among Adenocarcinoma (ADC), Squamous Cell Carcinoma (SCC),
and Control Pools (p  0.01)
Accession No. Protein pa
Average Spectral Count
TrendADC SCC Clinic PLuSS
P02763b Alpha-1-acid glycoprotein 1 1.92E-11 11.3 5.6 1.6 2 Up
P12081b Histidyl-tRNA synthetase, cytoplasmic 1.63E-07 2.3 5.2 2.1 2.6 Up
P02735b Serum amyloid A protein 3.85E-06 16.2 5.4 2.2 1 Up
P19652b Alpha-1-acid glycoprotein 2 1.81E-05 5.7 4.7 2.5 1.8 Up
P02741–1b Isoform 1 of C-reactive protein 5.98E-05 5.6 1 0.5 0.1 Up
P01880–1b Isoform 1 of Ig delta chain C region 0.0001 1.5 2.1 0.1 0 Up
P08603–1 Isoform 1 of complement factor H 0.0003 247.3 301.4 247.1 240.5 Up
O14511–1b Isoform 1 of pro-neuregulin-2, membrane-bound isoform 0.0005 1.4 2.1 0.8 0.6 Up
A0A5C9b IGLV2–14 protein 0.0006 15.1 19 8.6 9.5 Up
P00738b Haptoglobin 0.0007 37.4 18.5 18.7 14.3 Up
Q569J1 IGHA1 protein 0.0010 3 9.6 1.1 1.2 Up
Q92765 Secreted frizzled-related protein 3 0.0010 2.6 3.6 2 2.2 Up
Q9Y4E5–4 Isoform 4 of zinc finger protein 451 0.0010 2.4 5.3 1.7 2.1 Up
Q9UCK9b Serum amyloid A isotype 2 alpha protein (fragment) 0.0014 3.2 0 0.1 0 Up
P01877b Ig alpha-2 chain C region 0.0015 6.7 10.5 3.5 4.2 Up
Q8IY92–1b Isoform 1 of BTB/POZ domain-containing protein 12 0.0016 1.4 0.9 0.2 0 Up
P01860b Ig gamma-3 chain C region 0.0023 7.5 12.4 3.1 4.2 Up
P02671–1 Isoform 1 of Fibrinogen alpha chain 0.0024 5.9 2.4 2.6 1.4 Up
Q12988b Heat shock protein beta-3 0.0030 1.2 0.6 0.2 0.3 Up
Q9GZP7 Vomeronasal type-1 receptor 1 0.0040 0.2 1.5 0.5 0.4 Up
Q7LFX5–2 Isoform 2 of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase 0.0051 2.6 4 1.5 1.8 Up
P22415 Upstream stimulatory factor 1 0.0053 0.8 2.9 0.7 0.9 Up
P02753 Retinol-binding protein 4 0.0053 91.6 129.5 97.5 103.8 Up
Q9NYU1 UDP-glucose:glycoprotein glucosyltransferase 2 0.0055 0.7 1.2 0.3 0.2 Up
Q9NYK5–1b Isoform 1 of 39S ribosomal protein L39, mitochondrial 0.0057 1.4 0.7 0.1 0.6 Up
P33151 Cadherin-5 0.0058 0.7 2.1 0.6 1.2 Up
Q5VST9–1 Isoform 1 of obscurin 0.0061 1.3 3 1.9 1.1 Up
P00739–1b Isoform 1 of haptoglobin-related protein 0.0065 38.2 28.1 24.3 23 Up
A8MSL6 Putative uncharacterized protein APOA4 0.0066 0.3 1.6 0.1 0.9 Up
Q13224b Glutamate NMDA receptor subunit epsilon-2 0.0069 3.9 0.5 2 1.5 Up
Q6ZMN7–1 Isoform 1 of PDZ domain-containing RING finger protein 4 0.0070 1.9 1.1 0.9 1 Up
O75882–1 Isoform 1 of attractin 0.0073 9.9 13.4 10.6 8.6 Up
Q9UGU0–1 Isoform 1 of transcription factor 20 0.0079 1 1.2 0.4 0.3 Up
P05155 Plasma protease C1 inhibitor 0.0092 15.1 13.5 13.1 10.2 Up
P51452 Dual specificity protein phosphatase 3 0.0095 4.1 2.7 3.5 3.1 Up
P02655b Apolipoprotein C-II 0.0000 7.7 7.5 12.4 11.7 Down
P02751–1b Isoform 1 of fibronectin 0.0000 107.9 121.6 132.6 143 Down
P06396–1b Isoform 1 of gelsolin 0.0003 40.7 45 51.7 51.1 Down
O75636–1 Isoform 1 of ficolin-3 0.0004 5.2 2.6 7.2 5.9 Down
P04114b Apolipoprotein B-100 0.0006 279.3 247.9 327.3 313.8 Down
P02746b Complement C1q subcomponent subunit B 0.0006 2.9 3.2 4.8 5.6 Down
P51884b Lumican 0.0006 20 26.7 26 25.1 Down
P02765b Alpha-2-HS-glycoprotein 0.0007 126.9 198 170.5 166.8 Down
Q96KN2b Beta-Ala-His dipeptidase 0.0017 1.8 1.2 3.6 3.2 Down
Q96PD5–1 Isoform 1 of N-acetylmuramoyl-L-alanine amidase 0.0026 23.6 30.2 29.6 29.3 Down
P00742b Coagulation factor X 0.0032 3.8 2.5 5.3 4.9 Down
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 0.0074 72.2 64.1 79.5 76.3 Down
P04196 Histidine-rich glycoprotein 0.0085 31.8 37 41 40.9 Down
Q2VWA4–1b Isoform 1 of Ladybird homeobox corepressor 1-like protein 0.0087 0.1 0.4 1 1 Down
a The p value refers to the minimum p value of the resultant p values from the three negative binomial model-based comparisons (all cases vs. all controls; adenocarcinoma cases
vs. all controls; and squamous cell carcinoma vs. all controls). The trend for the level of individual protein expression is based on the comparison of the average of all case pools
compared with the average of all control pools. Spectral counts are normalized based on total spectral counts for each sample.
b Significant based on the Wilcoxon rank sum test with the same p value criteria.
ADC, adenocarcinoma; SCC, squamous cell carcinoma; clinic, clinical controls with computed tomography (CT)-detected nodules but with nonmalignant disease as determined
by biopsy; PLuSS, Pittsburgh Lung Screening Study healthy controls; Ig, immunoglobulin.
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abundance in only one histological subtype of NSCLC (ad-
enocarcinoma or squamous cell carcinoma). Applying a p
value cutoff of 0.01 for at least one of these comparisons
yielded a total of 49 candidate proteins (Table 2), with 35 of
them up and 14 down in observed abundance for the pooled
lung cancer samples comparing the average of all cases to all
controls. The false-positive rate was estimated to be 25%
based on the sequential p value method proposed by Benja-
mini and Hochberg,16 using the minimum p values of the
three comparisons as the input p values.
We also tested the discriminatory power of these se-
lected proteins using unsupervised hierarchical clustering. As
shown in Figure 2, the spectral counts for these proteins
resulted in near complete separation of the case pools from
the control pools with only two exceptions, case pool P15 and
clinical control pool P18. The selected features are also
robust in separating adenocarcinoma pools from squamous
cell carcinoma pools. Within the cluster of case pools (cluster
1 in Figure 2), all nine adenocarcinoma pools are clustered
together (cluster 1a), and four of five squamous cell carci-
noma pools within cluster 1 are clustered together (cluster
1b). Only one squamous cell carcinoma pool (P11) is clus-
tered together with the adenocarcinoma pools.
Bioinformatics Analysis of Selected Features
IPA tools17 were used to identify the functional attri-
butes of the 49 potential lung cancer-selective proteins. The
analysis showed significant enrichment of proteins related to
a number of different biological functions such as neurologic
disease, cellular movement, organismal survival, embryonic
development, renal and urological disease, cancer, and in-
flammatory responses, in the list of proteins with differential
abundance in lung cancer (Table 3). A total of 19 molecules
are associated with organismal survival, cell cycle, and can-
cer pathways, with ERK1/2, p38 MAP kinase, and NFB as
the key molecules in the network.
Adenocarcinoma and squamous cell carcinoma are two
major subtypes of NSCLC. To see whether these two sub-
types are related to differential physiological responses, we
applied comparative functional enrichment analysis using
IPA tools to compare features with differential abundance in
the adenocarcinoma case pools, compared with the squamous
cell carcinoma case pools. The selection of features was
based on a p value 0.05. A total of 79 and 68 significant
features were selected for adenocarcinoma and squamous cell
carcinoma, respectively, with 14 of them being common for
both subtypes. Results showed differential enrichment of
proteins for several different functional categories for these
two NSCLC subtypes (Table 4). In particular, a larger set of
adenocarcinoma-selective proteins is involved in inflamma-
tory response or has been previously implicated in inflam-
matory-related diseases such as infectious, respiratory, gas-
trointestinal, and dermatological diseases, suggesting that
patients with lung adenocarcinoma may experience a greater
proinflammatory response. In contrast, more squamous cell
carcinoma-selective features are involved in molecular trans-
port, small molecule biochemistry, endocrine system disor-
ders, and vitamin and mineral metabolism. These results
suggest that these two different NSCLC subtypes of lung
cancer are associated with different physiological responses.
Verification of Selected Features Using
Quantitative Mass Spectrometry by MRM
To verify the legitimacy of using spectral counting data
for relative quantitation of protein abundance, we used MRM
assays to confirm the spectral counting-derived abundance of
four selected proteins from our study: serum amyloid A
FIGURE 2. Hierarchical clustering based on spec-
tral counting of the selected significant proteins
(p  0.01). Both sample distance (column dis-
tance) and protein feature distance (row distance)
were based on Pearson’s correlation, and the link-
age of both clusters was based on average link-
age. The values for spectral counts were standard-
ized for each protein. Green and red colors in the
clustering represent under- and overexpression,
respectively. The selected features are able to sep-
arate case pools (pools P01–P16) from the con-
trols (pools P17–P32) with only two exceptions
(pools P15 and P18). P01–P09, adenocarcinoma
pools (red labels); P11–P16, squamous cell carci-
noma pools (purple); P17–P24, clinical control
pools (blue); and P25–P32, healthy control pools
(green).
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TABLE 3. Functional Enrichment Analysis for NSCLC-Selective Proteins Using the Ingenuity Pathway Analysis Tools
Category p Proteins N
Neurologic disease 7.92E-08 CNDP1, GRIN2B, SERPING1, APOB, FN1, ORM2, OBSCN (includes EG:84033), APOC2,
GSN, IGHA2, ORM1, HRG, F10, HP, CRP
15
Cellular movement 7.36E-07 SERPING1, FN1, APOB, HARS, GSN, HRG, ORM1, F10, HP, CDH5, LUM, CRP, FGA,
SAA1
14
Organismal survival 2.21E-06 HP, SERPING1, ORM2, APOB, CRP, CFH, GSN, ORM1 8
Embryonic development 1.21E-05 F10, NRG2, FN1, AHSG, HARS, GSN, FGA, SAA1, RBP4 9
Renal and urological disease 1.78E-05 GRIN2B, F10, HP, FN1, CRP, CFH, GSN, SAA1 8
Cancer 1.78E-05 GRIN2B, SERPING1, FN1, FRZB, PGLYRP2, AHSG, ZNF451, OBSCN (includes EG:84033),
GSN, HRG, ORM1, F10, HP, IGHG3, CDH5, ATRN, CRP, CFH, FGA, SAA1, RBP4
21
Inflammatory response 1.90E-05 SERPING1, FN1, ORM2, AHSG, C1QB, IGHA2, GSN, ORM1, FCN3, F10, HP, IGHG3,
ATRN, LUM, CRP, CFH, FGA, SAA1
18
Cell cycle 2.05E-05 NRG2, FN1, AHSG 3
Tissue development 5.38E-05 SERPING1, FN1, NRG2, AHSG, GSN, F10, CDH5, ATRN, CRP, LUM, FGA, SAA1, RBP4 13
Cell-to-cell signaling and
interaction
5.38E-05 F10, SERPING1, IGHG3, FN1, CDH5, ATRN, AHSG, CRP, CFH, FGA, GSN, SAA1 12
Each category may contain multiple functions/diseases. p value refers to the minimum p value for the significance of enrichment for different functions/diseases within the
category. N is the number of NSCLC-selective proteins involved in the category.
NSCLC, non-small cell lung cancer.
TABLE 4. Comparative Functional Enrichment Analysis for Proteins with Altered Expression in Different NSCLC Subtypes
(Adenocarcinoma vs. Squamous Cell Carcinoma) Using the Ingenuity Pathway Analysis Tools
Categories
Adenocarcinoma Squamous Cell Carcinoma
paProteins N Proteins N
Molecular transport FN1, APOB, APOC2, SERPINA7, GSN, ORM1,
SAA1
7 APOE, SELL, APOB, C3, APOM, APOC2,
ORM1, CDH5, C4A, CFH, GC, SAA1,
ATM
13 0.0705b
Small molecule biochemistry ITGB2, SERPING1, HP, FN1, APOB, SERPINA1,
APOC2, GSN, SERPINA7, DNMT1, SAA1
11 APOE, C3, APOB, APOM, MSH3, APOC2,
CHST15, CDH5, REV1, C7, USF1, C4A,
CFH, GC, SAA1, RBP4, ATM
17 0.0882b
Endocrine system
disorders
UBR1, APOB, CDNP1, GRIN2B, NRG2 5 CNDP1, APOE, GRIN2B, SHKBP1, SELL,
APOM, APOB, NRG2, C3, MSH3, FAT3,
SYNE1, SERPINA3, DLC1, CHST15, C7,
GC, RBP4, FHOD3 (includes EG:80206)
19 0.0004b
Vitamin and mineral
metabolism
APOB, SERPINA1, ORM1, SAA1 4 APOE, SELL, C3, APOB, GC, SAA1,
ORM1, RBP4
8 0.0829c
Inflammatory response SERPING1, FN1, APOB, C9, C1QB, ORM1,
IGHG3, PROS1, LUM, C7, SERPINA1, SAA1,
STAT6, TIAM1, ORM2, AHSG, COL2A1, GSN,
ITGB2, KLKB1, HP, S100A9, CRP, AOX1, FGA
25 APOE, SELL, APOB, C3, ORM2,
SERPINA3, C1QB, IGHA2, ORM1,
FCN3, F10, IGHG3, ATRN, C4A, C7,
CFH, GC, SAA1, ATM
19 0.6248b
Infectious disease HUWE1, STAT6, GRIN2B, FN1, C9, ITGB2, HP,
IGHG3, S100A9, PROS1, CRP, LUM,
SERPINA1, TROVE2, TCF20
15 F10, C3, GRIN2B, IGHG3, TCF20 5 0.0402b
Respiratory disease GRIN2B, ITGB2, STAT6, HP, FN1, S100A9, CRP,
ACO2, AHSG, SERPINA1, AZGP1, TROVE2
12 APOE, GRIN2B 2 0.0088c
Gastrointestinal disease MAST2, STAT6, ADAMTSL3, TIAM1, APOB, C9,
GSN, KLKB1, ITGB2, ANK2, CRP, KRT2,
SNCAIP, TNFRSF19, GADL1, DNMT1, TCF20
17 GC, A1BG, TCF20, APOB 4 0.0046c
Dermatological diseases
and conditions
STAT6, GRIN2B, SERPING1, FN1, UBR1,
COL2A1, KLKB1, ITGB2, IGHG3, S100A9,
PROS1, CRP, KRT2, SERPINA1, COL11A2,
SAA1, FCGBP (includes EG:8857), IGHD
18 ZNF331, GRIN2B, APOE, SELL, IGHG3,
C4A, SAA1, IGHD
8 0.0808b
a p values were calculated using 2 test of independence (b) or Fisher’s exact test (c) for the significance of differential enrichment of proteins with altered expression in the
specified functional categories. The total numbers of features included for Ingenuity Pathways Analysis (IPA) are 79 and 68 for adenocarcinoma pools and squamous cell carcinoma
pools, respectively.
NSCLC, non-small cell lung cancer.
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(SAA), alpha-1-acid glycoproteins 1, and 2 (AAG1 and
AAG2), which were observed to have significantly higher
spectral counts in the lung cancer versus control serum pools,
and clusterin which had equivalent spectral counts across the
case and control pools. One unique surrogate peptide was
selected for each of these proteins, and three transition ions
were monitored for each peptide (Table 5). The MRM assays
were carried out in triplicate for four selected adenocarci-
noma lung cancer serum pools and five selected PLuSS
control pools, and the mass chromatogram peak areas from
triplicate runs were averaged for each peptide/sample pair.
Figure 3 shows the scatterplot distribution of the logarithm of
average MRM peak areas (base 10) according to the case/
control status of the pool. The mean spectral counts and
MRM peak areas are listed in Table 3. Similar to what we
observed based on spectral counting-derived abundance, the
MRM peak areas for SAA, AAG1, and AAG2 were much
higher in lung cancer serum pools compared with control
pools, whereas similar MRM peak areas were seen for the
selected clusterin peptide. Comparative analysis using Stu-
dent’s t test for MRM peak areas (after log transformation)
indicated that the difference between the selected case and
control pools remains statistically significant for SAA1 and
AAG1 and of marginal significance for AAG2 (Table 5).
Overall, these results indicate strong correlation between
spectral counting-derived abundance and MRM peak area-
derived abundance, supporting the validity of using spectral
counting-derived protein abundance to identify differentially
abundant proteins.
DISCUSSION
Toward our overall goal to identify potential serum-
based biomarkers to predict lung cancer in high-risk subjects,
including patients with CT-detected pulmonary nodules, we
applied bottom-up LC-MS/MS-based proteomic analyses to a
large set of pooled clinically ascertained NSCLC case sera
and matched controls. Pooled sera were subjected to
MARS14 depletion, followed by in solution trypsin digestion,
and LC-MS/MS analysis. A large number of low-abundant
proteins were identified, suggesting relatively broad coverage
of the serum proteome. By comparing the proportions of the
14 MARS14-depleted serum proteins in serum protein mass
versus total spectral counts, we found differential effec-
tiveness of MARS14 spin cartridges in depletion of differ-
ent proteins, with depletion efficiency highest for serum
albumin. The differential effectiveness probably reflects
the quality and quantity of antibodies used in the MARS14
spin cartridges.
The relative quantitation of protein abundance in our
study was achieved by spectral counting. To increase the
reliability of the spectral counting, we analyzed our samples
in triplicate and only included proteins with 	2 different
peptides and with more than 15 total spectral counts. We
recognize that this increase in reliability comes with a sub-
FIGURE 3. MRM analysis and quantitation of clusterin (CLU), serum amyloid A (SAA), alpha-1-acid glycoprotein 1 (AAG1),
and alpha-1-acid glycoprotein 2 (AAG2). Spectral counting data indicated that the SAA, AAG1, and AAG2 were differentially
abundant between the case and control pools, whereas CLU abundance was independent of case/control pool status. Scatter-
plot distributions of the logarithm (base 10) of MRM peak areas (average of triplicate MRM assays) according to case/control
pool status are shown.
TABLE 5. Comparative Analysis of Protein Abundance Measurements by Spectral Counting and MRM
Protein
Mean
Spectral
Counta MRM Assay MRM Mean Peak Areasa
ADC PLuSS Peptide Sequence Transitions ADC PLuSS p
SAA 9 0 SFFSFLGEAFDGAR 1089.531117.1, 1047.6, 931.0 7.95E  06 1.36E  05 0.0004
AAG1 2.5 0.2 YVGGQEHFAHLLILR 876.931120.3, 982.4, 835.3 5.83E  05 7.24E  04 0.0293
AAG2 2.75 0 EHVAHLLFLR 617.83968.6, 869.4, 661.4 1.03E  06 1.96E  05 0.0503
CLU 6.75 7 ASSIIDELFQDR 697.331305.5, 922.5, 678.4 8.66E  07 8.01E  07 0.5871
a Mean spectral counts and MRM mean peak areas were determined from triplicate LC-MS/MS and MRM-MS runs, respectively. Mean spectral counts are for corresponding
proteins, not just for the specific peptide selected for the MRM assay.
MRM, multiple reaction monitoring; LC-MS/MS, liquid chromatography-tandem mass spectrometry; ADC, adenocarcinoma; PLuSS, Pittsburgh Lung Screening Study.
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stantial sacrifice with a large number of proteins excluded
from quantitation. Of the total of 20,916 proteins identified
from the combined 93 LC-MS/MS runs, 11,549 proteins were
identified with 	2 different peptides; however, only 1127 of
them had more than 15 total spectral counts.
Although spectral counting has gained increased pop-
ularity for relative quantitation of protein abundance in label-
free LC-MS/MS workflows, statistical tools for spectral
counting-based comparative analysis are still immature. As
spectral counting is count data in nature, Poisson regression
has been used by some researchers for comparative analysis
of spectral counting-based data.18,19 Nevertheless, Poisson
regression assumes that the dependent variable (herein spec-
tral counting) follows the Poisson distribution, and therefore,
the variance is equal to the mean. We tested the performance
of Poisson regression on our dataset and found that approx-
imately 10% of the resultant Poisson regression models had
deviance/degree of freedom (df) more than 2, indicating the
presence of overdispersion for some proteins (data not
shown). Therefore, we decided to use a negative binomial
regression model, a useful alternative for data overdispersed
for the Poisson regression model by incorporating an addi-
tional parameter to adjust variance independently of the
mean.13 We applied negative binomial regression to the 1127
proteins with 	2 different peptides and with more than 15
total spectral counts. A robust discovery set (N  49) of lung
cancer-selective proteins was identified. We also compared
the negative binomial analysis results with those obtained
using the nonparametric Wilcoxon rank sum test. The same
feature selection criteria using the Wilcoxon rank sum test
yielded a smaller set of significant features (N  40), with 28
of them also detected by negative binomial regression. A
number of the selected proteins have been identified in the
previously referenced proteomics studies,9,10 such as alpha-
1-acid glycoprotein 1, N-acetylmuramoyl-L-alanine amidase,
gesolin, haptoglobin, ficolin-3, and beta-ala-his dipeptidase.
Consistent with the important role of inflammation in tumor
development,20 functional analysis by IPA showed a signifi-
cant enrichment of proteins associated with inflammatory
responses or acute phase reaction.
The robustness of the spectral counting-derived
abundance for these selected proteins in discriminating
case pools and control pools was tested using unsupervised
hierarchical clustering, a statistical method for grouping
subjects based on similarity of measured characteristics.
The resulting analysis showed almost complete separation
between the NSCLC case pools and control pools with the
exception of only one case pool (P15) and one clinical
control pool (P18). Nevertheless, it is worth mentioning
that pool P15, although being clustered together with the
control pools, also shared substantial similarity in terms of
protein abundance with the subcluster (cluster 1b) consist-
ing of four other squamous cell carcinoma pools. Also
worth noting is the fact that many of the clinical control
subjects, although cancer free at the time of serum sample
collection, had nonmalignant lung disease as demonstrated
by the presence of CT-detected pulmonary nodules. The
mixed clustering of the clinical control pool P18 with the
NSCLC case pools may, therefore, be the result of the
contributions of inflammatory proteins included in our list
of significant features. Nonetheless, our analysis was able
to separate the majority of clinical control pools (seven of
the eight pools) from NSCLC case pools, suggesting that
our selected features may potentially be useful in increas-
ing the specificity of thoracic CT scans for lung cancer
screening, thus reducing the need of invasive thoracic
procedures for patients with CT-detected indeterminate
nodules.
Adenocarcinoma and squamous cell carcinoma are the
two most common NSCLC subtypes. These two NSCLC
subtypes have been shown to differ significantly both in terms
of their clinical behavior and molecular signatures.21–23 In-
terestingly, by comparing significant features selected based
on the comparison of adenocarcinoma case pools with all
control pools, versus significant features selected based on
the comparison of squamous cell carcinoma case pools with
all control pools using comparative functional analysis with
IPA tools, we found differential enrichment of several func-
tional categories for these two NSCLC subtypes. Patients
with lung adenocarcinoma seem to experience a greater
proinflammatory response based on the observed alterations
in the serum proteome. More inflammatory response-related
proteins are differentially abundant in adenocarcinoma case
pools compared with squamous cell carcinoma case pools.
Significantly higher numbers of adenocarcinoma-selective
proteins have been previously associated with several inflam-
matory-related conditions such as infectious, respiratory, gas-
trointestinal, and dermatological diseases. Also, among the
inflammatory-related proteins differentially expressed in both
of these NSCLC subtypes, such as AAG1, AAG2, and SAA,
the magnitude of change seems to be larger for the adeno-
carcinoma case pools (Table 2). In contrast, patients with
squamous cell lung carcinoma seem to experience a greater
response in plasma lipid physiology, with more differentially
abundant proteins involved in molecular transport and small
molecule biochemistry. Both of these two functional catego-
ries involve proteins responsible for transport, secretion,
clearance, and/or metabolism of lipids. Patients with squa-
mous cell carcinoma also seem to have a greater deregulation
in their endocrine system, with a greater number of differen-
tially abundant proteins associated with endocrine system
disorders. We also observed a greater magnitude of change in
squamous cell lung carcinoma for endocrine system-related
features shared by both subtypes, such as neuregulin-2, apo-
lipoprotein B-100, and beta-ala-his dipeptidase (Table 2).
Interestingly, the majority of these proteins (18/19) have been
previously related to diabetes mellitus. Smoking has been
shown to contribute to endocrine disorders including the
development of insulin resistance and, hence, type 2 diabetes
mellitus.24 As squamous cell carcinoma is the more frequent
NSCLC subtype diagnosed in heavy smokers, it is not clear
whether our observation is a reflection of more heavy smok-
ing in the squamous cell carcinoma cases in our study.
In summary, we have presented data from an initial
comparative proteomics study for lung cancer serum bio-
marker discovery and generated a robust discovery set of
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candidate proteins with altered abundance in lung cancer.
Functional analyses support the important roles of inflamma-
tion in cancer and also reveal differential physiological re-
sponses related to different NSCLC subtypes. The clinical
utility of these candidate lung cancer serum biomarker pro-
teins needs to be validated with additional analytical plat-
forms and in independent case/control sample sets.
ACKNOWLEDGMENTS
Supported by Hirtzel Foundation Postdoctoral Fellow-
ship (to X.Z.), P50 CA90440 NCI SPORE in Lung Cancer (to
J.M.S.), and NCI Early Detection Research Network Bio-
marker Discovery Laboratory, U01 CA084968 (to W.L.B.).
REFERENCES
1. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on
prognosis in patients with non-small cell lung cancer: the role of
segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg
2005;129:87–93.
2. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the
United States, 2010: a reviews of current American Cancer Society
guidelines and issues in cancer screening. CA Cancer J Clin 2010;60:
99–119.
3. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer:
screening and detection with low-dose spiral CT versus radiography.
Radiology 1996;201:798–802.
4. Welch HG, Woloshin S, Schwartz LM, et al. Overstating the evidence
for lung cancer screening: the International Early Lung Cancer Action
Program (I-ELCAP) study. Arch Intern Med 2007;167:2289–2295.
5. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung
Screening Study (PLuSS): outcomes within 3 years of a first computed
tomography scan. Am J Respir Crit Care Med 2008;178:956–961.
6. Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cyto-
keratin markers in non-small cell lung cancer: a study of tissue poly-
peptide antigen and cytokeratin 19 fragments. Chest 2003;124:622–632.
7. Pastor A, Mene´ndez R, Cremades MJ, et al. Diagnostic value of SCC,
CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir
J 1997;10:603–609.
8. Rapellino M, Niklinski J, Pecchio F, et al. CYFRA 21–1 as a tumour
marker for bronchogenic carcinoma. Eur Respir J 1995;8:407–410.
9. Okano T, Kondo T, Kakisaka T, et al. Plasma proteomics of lung cancer
by a linkage of multi-dimensional liquid chromatography and two-
dimensional difference gel electrophoresis. Proteomics 2006;6:3938–
3948.
10. Heo SH, Lee SJ, Ryoo HM, et al. Identification of putative serum
glycoprotein biomarkers for human lung adenocarcinoma by multilectin
affinity chromatography and LC-MS/MS. Proteomics 2007;7:4292–
4302.
11. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and
estimation of relative protein abundance in shotgun proteomics. Anal
Chem 2004;76:4193–4201.
12. Old WM, Meyer-Arendt K, Aveline-Wolf L, et al. Comparison of
label-free methods for quantifying human proteins by shotgun proteom-
ics. Mol Cell Proteomics 2005;4:1487–1502.
13. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and
rates: Poisson, overdispersed Poisson, and negative binomial models.
Psychol Bull 1995;118:392–404.
14. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reac-
tion monitoring assays for major plasma proteins. Mol Cell Proteomics
2006;5:573–588.
15. Kuzyk MA, Smith D, Yang J, et al. Multiple reaction monitoring-based,
multiplexed, absolute quantitation of 45 proteins in human plasma. Mol
Cell Proteomics 2009;8:1860–1877.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a
practical and powerful approach to multiple testing. J R Statist Soc B
1995;57:289–300.
17. Ingenuity Systems. The Networks and Functional Analyses were Gen-
erated through the Use of Ingenuity Pathways Analysis. Available at:
www.ingenuity.com. Accessed June 22, 2010.
18. Chourey K, Thompson MR, Shah M, et al. Comparative temporal
proteomics of a response regulator (SO2426)-deficient strain and wild-
type Shewanella oneidensis MR-1 during chromate transformation.
J Proteome Res 2009;8:59–71.
19. Sprung RW Jr, Brock JW, Tanksley JP, et al. Equivalence of protein
inventories obtained from formalin-fixed paraffin-embedded and frozen
tissue in multidimensional liquid chromatography-tandem mass spec-
trometry shotgun proteomic analysis. Mol Cell Proteomics 2009;8:
1988–1998.
20. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and
cancer. Cell 2010;140:883–899.
21. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North
Am 2007;45:21–43.
22. Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification
of non-small cell lung carcinomas and survival prediction. PLoS One
2010;5:e10312.
23. Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differen-
tiates histology and predicts survival of lung cancer. Clin Cancer Res
2010;16:430–441.
24. Kapoor D, Jones TH. Smoking and hormones in health and endocrine
disorders. Eur J Endocrinol 2005;152:491–499.
Zeng et al. Journal of Thoracic Oncology • Volume 6, Number 4, April 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer734
